Internal medicine

Pathology

Clinical endpoint

Placebo

Double blind

Gastroenterology

Rheumatology

Placebo-controlled study

Alternative medicine

Psoriatic arthritis

Arthritis

Clinical trial

Medicine

The Lancet

Guselkumab, a human monoclonal antibody that specifically inhibits IL-23 by binding the cytokine's p19 subunit, was efficacious and demonstrated an acceptable benefit–risk profile in patients with active psoriatic arthritis who were naive to treatment with biologics. These data support the use of selective inhibition of IL-23 to treat psoriatic arthritis.

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial